Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Daniel Spratt MD

Daniel E. Spratt MD

Chairman and Vincent K Smith Professor, Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio

Daniel Spratt, MD, is the Vincent K. Smith Professor and Chairman of the Department of Radiation Oncology at University Hospitals Seidman Cancer Center/Case Western Reserve University School of Medicine.  Dr. Spratt completed his medical training at Vanderbilt University and residency training in Radiation Oncology at Memorial Sloan Kettering Cancer Center.  He joined the faculty at the University of Michigan in 2015 and became the fastest tenured Professor in the University’s history.  While at the University of Michigan he was the Chief of the Genitourinary Radiotherapy Program, Associate Chair of Clinical Research, Fellowship Director, the Laurie Snow Endowed Research Professor, Director of Spine Oncology and co-Chair of the Genitourinary Clinical Research Team for the Rogel Cancer Center.  Dr. Spratt is an international expert in prostate cancer and served on the national NCCN prostate cancer guidelines committee, serves as the Chair of the Intact Prostate Cancer Subcommittee within NRG Oncology, and serves on the National Cancer Institute’s Genitourinary Steering Committee.  He runs an NIH funded translational research team focused on the development and validation of prognostic and predictive biomarkers, has published over 300 peer-reviewed manuscripts, and has served as the principal investigator on numerous national and international clinical trials. He has mentored over 40 students, residents, fellows, and faculty, and has received numerous teaching and mentorship awards. 


Dr. Spratt reports the following:
  • Personal fees: Janssen, AstraZeneca, Blue Earth, Boston Scientific
  • Funding, Janssen